Insider Sells Shares of Mesa Laboratories, Inc.

On June 22, 2026, Brian Archbold, the SVP of Operations at Mesa Laboratories, Inc. (NasdaqGS: MLAB), sold 2,516 shares of the company. The shares were sold at an average price of $89.50, totaling about $225,182. This transaction was not planned under a Rule 10b5-1 plan.

Other Institutional Activity in Mesa Laboratories

Long Path Partners LP significantly increased its holdings in Mesa Laboratories, adding 178,360 shares to reach a total of 405,583 shares valued at approximately $35.9 million. BlackRock, Inc. slightly reduced its position by 4,815 shares, ending with 393,851 shares worth around $34.8 million. Boston Partners boosted its stake by 55,335 shares, bringing its total to 268,711 shares valued at $23.8 million. Select Equity Group, L.P. also increased its holdings by 29,450 shares, totaling 235,885 shares valued at $20.9 million. Additionally, Vanguard Capital Management LLC initiated a new position with 232,643 shares valued at $20.6 million.

Mesa Laboratories, Inc. Stock Down 28.7%

Shares of Mesa Laboratories, Inc. traded near $93.23 on Tuesday. The company has a market capitalization of $515.1 million and a P/E ratio of 77.0, with a forward P/E of 7.6. Its beta stands at 0.927, indicating lower volatility compared to the market. The stock's 52-week range spans from $55.45 to $113.99, with a 50-day moving average of $101.99 and a 200-day moving average of $84.97. The current ratio is 1.717, while the quick ratio is 1.174, and the debt-to-equity ratio is 90.65.

Recent Earnings

Mesa Laboratories reported revenues of $249.1 million, reflecting a growth rate of 2.6%. The company's net margin is 2.7%, and it has a return on equity of 3.9%. Earnings per share stood at $1.21. The next earnings report is expected on August 5, 2026.

Dividend

Mesa Laboratories pays an annual dividend rate of $0.64, yielding 0.67%. The dividend payout ratio is 52.9%.

Insider Buying and Selling at Mesa Laboratories, Inc.

On June 22, 2026, several insiders at Mesa Laboratories engaged in stock transactions. Brian Archbold, SVP Operations, sold 2,516 shares at $89.50. Lyndsey Elizabeth Crennen, Chief Accounting Officer, sold 442 shares at the same price. John Sakys, CFO, sold 2,827 shares at $89.50. Earlier, on June 18, 2026, Sakys purchased 2,282 shares at $95.10, and Archbold bought 1,859 shares at the same price.

Analysts Set New Price Targets

Wells Fargo maintained its hold rating on Mesa Laboratories with a price target of $94.00 on February 4, 2026. Evercore ISI previously maintained a buy rating with a target of $106.00 on July 2, 2024. The consensus target price is $112.00, based on two analyst opinions.

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. designs and manufactures tools and quality control products for the life sciences and various industries worldwide. Headquartered in Lakewood, Colorado, the company operates in sectors such as sterilization and disinfection control, clinical genomics, biopharmaceutical development, and calibration solutions. Under the leadership of CEO Dr. Siddhartha Chandrakant Kadia, Mesa employs 717 people.

Bottom Line

Insider transactions at Mesa Laboratories, including those by Brian Archbold, highlight ongoing management activity. Investors often track such moves for potential insights, although they do not necessarily indicate future stock performance. Mesa Laboratories continues to attract institutional interest, with notable changes in holdings by major funds.